What Is LIQUISTANE 25MG / ML | 60ML?
Exemestane, sold under the brand name Aromasin, is a steroidal aromatase inhibitor. The FDA initially approved it for the treatment of advanced breast cancer in 1999. Later, it received approval for the adjuvant treatment of postmenopausal women with estrogen receptor-positive early breast cancer in 2005. Furthermore, it has been used in doping to enhance athletic performance, thus banned by the World Anti-Doping Agency (WADA). At Pinnacle Peptides, exemestane for sale is exclusively available for research and experimentation.
Structure Of LIQUISTANE 25MG / ML | 60ML
IUPAC Name: (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
Synonyms: 107868-30-4, Aromasin
Molecular Formula: C20H24O2
Molecular Weight: 296.4 g/mol
CAS number: 107868-30-4
PubChem CID: 60198
Mechanism Of LIQUISTANE 25MG / ML | 60ML
Exemestane structurally resembles 4-androstenedione, a natural substrate of the aromatase enzyme. Research shows that exemestane competes with testosterone and androstenedione and binds to the active site of the enzyme through a covalent bond, resulting in irreversible inhibition of aromatase. Aromatase is responsible for the transformation of androgen into estrogen. Blocking of aromatase in postmenopausal women decreases the levels of estrogen and suppresses the proliferation of hormone-sensitive breast cancer cells.
1. Early Stage Breast Cancer
Tamoxifen as an adjuvant treatment has been shown to decrease the risk of recurrence by 47% when administered for five years post-surgery. However, breast cancer relapses despite tamoxifen treatment in certain cases. Research shows that alternative endocrine therapies might show improved efficacy in such scenarios.
The Intergroup Exemestane Study (IES) found that the patients who switched to exemestane, following 3 years of tamoxifen therapy, experienced a significant reduction in the risk of recurrence by 32%. Plus, the incidence of contralateral breast cancer was notably lower in the exemestane group compared to the tamoxifen group. The study concluded that exemestane improved the risk of disease-free survival as compared to tamoxifen .
Similarly, The Tamoxifen Exemestane Adjuvant Multinational (TEAM) Phase 3 trial was conducted to compare the long-term efficacy of exemestane monotherapy with sequential treatment. The results indicated similar disease-free survival rates in both groups after 5 years. Notably, the sequential treatment group exhibited a higher incidence of gynecological symptoms, venous thrombosis, and endometrial abnormalities, while the exemestane-only group experienced more musculoskeletal issues .
2. Breast Cancer in Premenopausal Women
The results from the SOFT and TEXT trial suggest that exemestane in combination with ovarian suppression significantly decreased the recurrence rates of breast cancer in premenopausal women as compared to those taking tamoxifen and ovarian suppression therapy .
3. Advanced Stage Breast Cancer
Research suggests that resistance to breast cancer treatment is associated with the interaction between estrogen receptor signaling and PI3/AKT/mTOR pathway. Thus, co-targeting these pathways might improve outcomes in patients with advanced-stage breast cancer.
The results of the BOLERO-2 trial support the efficacy of combination therapy, using exemestane plus everolimus, as first-line treatment for disease recurrence in patients who don’t respond to non-steroidal aromatase inhibitors. Furthermore, the study suggested the earlier introduction of combination treatment in estrogen receptor-positive advanced breast cancer .
Similarly, another study revealed that exemestane prolongs survival time and delays the progression of cancer as compared to megestrol acetate in patients with advanced-stage breast cancer who experienced failure of tamoxifen .
4. Breast Cancer Prevention
Exemestane has been shown to prevent the incidence of contralateral breast cancer among postmenopausal women. In a study involving 4560 postmenopausal women who were at high risk of breast cancer, exemestane decreased the risk of invasive breast cancer by 65% as compared to the control group. Furthermore, overall rates of both invasive and noninvasive breast cancers were lower in the exemestane group (0.35% vs. 0.77%) .
Exemestane is a steroidal aromatase inhibitor indicated for the treatment of breast cancer. It decreases the exposure of estrogen, thus reducing the proliferation of hormone-sensitive breast cancer cells. It has been shown to decrease the risk of breast cancer in women at high risk. Furthermore, it can reduce the incidence of cancer recurrence. It’s often abused by athletes to enhance performance. We don’t support its unwarranted use and offer exemestane purchase solely for research. Only buy exemestane if you are a qualified researcher.
- Coombes, R.C., et al., A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. New England Journal of Medicine, 2004. 350(11): p. 1081-1092.
- van de Velde, C.J., et al., Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet, 2011. 377(9762): p. 321-31.
- Pagani, O., et al., Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. New England Journal of Medicine, 2014. 371(2): p. 107-118.
- Beck, J.T., et al., Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2. Breast Cancer Research and Treatment, 2014. 143(3): p. 459-467.
- Kaufmann, M., et al., Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol, 2000. 18(7): p. 1399-411.
- Goss, P.E., et al., Exemestane for Breast-Cancer Prevention in Postmenopausal Women. New England Journal of Medicine, 2011. 364(25): p. 2381-2391.
What is Exemestane?
Exemestane, also known as Aromasin, is a medication classified as an aromatase inhibitor that is primarily used in the treatment of hormone receptor-positive breast cancer. It functions by lowering postmenopausal women's estrogen levels because estrogen has been shown to accelerate the growth of several breast cancer forms. In order to lower the chance of cancer recurrence, exemestane is frequently administered as an adjuvant medication following initial treatments like surgery or chemotherapy. In cases of advanced or metastatic breast cancer, it is also used. Exemestane serves to halt or decrease the growth of hormone receptor-positive breast cancer cells by limiting the production of estrogen, which contributes to better treatment outcomes.
Extensive research has been done on the aromatase inhibitor exemestane in the field of oncology, especially for the treatment of hormone receptor-positive breast cancer. Its effectiveness, safety, and possible applications have all been studied in various patient populations.
Exemestane's use as an adjuvant therapy for hormone receptor-positive breast cancer is a prominent field of study. Its efficiency in lowering the risk of cancer recurrence following initial treatments like surgery or chemotherapy has been tested in clinical trials. Exemestane, when used as adjuvant therapy, has been found to be superior to placebo or other hormonal therapies in terms of disease-free survival and overall survival.
The efficacy of exemestane in comparison to other aromatase inhibitors or tamoxifen, a popular hormonal therapy for hormone receptor-positive breast cancer, has also been the subject of comparison studies in exemestane research. Studies like this have looked into things like side effect profiles, overall survival rates, and rates of survival without disease. The MA.17 trial, which contrasted Exemestane and tamoxifen as extended adjuvant therapy, showed that Exemestane was superior in terms of lowering the chance of cancer recurrence.
Advanced or Metastatic Breast Cancer:
Exemestane studies has examined its effectiveness in advanced or metastatic breast cancer in addition to adjuvant therapy. Exemestane has been tested as a first- or second-line therapy option, either by itself or in conjunction with other medications. Exemestane has been proven to provide clinical advantages in this patient population, including tumor response rates and progression-free survival.
Safety and Tolerability:
Research on exemestane has been focused on determining the drug's safety and tolerability. Exemestane side effects include hot flashes, musculoskeletal problems, and bone density loss have all been the subject of studies looking at their occurrence and treatment. By figuring out ways to reduce side effects and improve treatment compliance, research has sought to improve patient care.
Biomarker and Predictive Studies:
Studies on biomarkers and predicting factors have been conducted in an effort to find the patients who will benefit from exemestane treatment the most. Through the investigation of genetic variants, hormone receptor status, and other molecular indicators that may affect responsiveness to Exemestane medication, these investigations have made it possible to develop more individualized treatment plans.
Where to Buy Exemestane
If you want to complete your search for the essential lab research chemical EXEMESTANE, you need to look no further. Pinnacle Peptides is going to provide you all your requirements of this chemical. The online store offers Exemestane for sale and all kinds of lab supplies as well as research materials at unbeatable prices. So whether you are gearing up for a lab research or an experiment, it is advised that you look up all your needs on the website to get the best quotes. You can stock up all your essential requirements easily from here. You will also get a wider range of supplies, all under one stop, making the whole shopping process streamlined. Best quality lab supplies available online from Pinnacle Peptides. We provide you various research materials and chemical supplies that have several applications in the field of research and medicine. You can buy Exemestane/Aromasin online in a vial of 25mg at our website. Whether you want a single vial or you want to purchase Exemestane in bulk, Pinnacle Peptides is your best online source for this item. All purchases and deliveries of the items are extremely easy for you to carry out your research. All that is required on your part is to find out what you want on the website, and select the amount of each, and place the order. International delivery is also provided which is what makes our online store one of the most trusted sources worldwide.
The products we offer are intended for laboratory research use only. In purchasing any of these items, the customer acknowledges that there are risks involved with consumption or distribution of these products. These chemicals are NOT intended to use as food additives, drugs, cosmetics, household chemicals or other inappropriate applications. The listing of a material on this site does not constitute a license to its use in infringement of any patent. All of the products will be handled only by qualified and properly trained professionals. All customers represent and warrant that through their own review and study that they are fully aware and knowledgeable about the following: Government regulations regarding the use of and exposure to all products. The health and safety hazards associated with the handling of the products they purchase. The necessity of adequately warning of the health and safety hazards associated with any products. Pinnacle Peptides reserves the right to limit and/or deny sales of products to any unqualified individuals if we have reason to believe that misuse will occur.